Riskpilot← Back to searchSign inGet full accessWellspect ApS
APSActiveCVR 42712744Maglebjergvej 10Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20213 employees
Revenue 2024
DKK 9,4M
-21% vs 2023
EBITDA margin
46.9%
-40% vs 2023
Equity ratio
26.7%
Financial strength
Net profit 2024
DKK 665K
-83% vs 2023
| Revenue | DKK 9,4M | -21% |
| EBITDA | DKK 4,4M | -40% |
| Net profit | DKK 665K | -83% |
| Total assets | DKK 36,2M | -9% |
| Equity | DKK 9,7M | -21% |
| Employees | 3 | — |
Legal name
Wellspect ApS
CVR number
42712744
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
28. september 2021
Share capital
DKK 40.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af formanden for bestyrelsen, af to bestyrelsesmedlemmer i forening, af et bestyrelsesmedlem i forening med en direktør eller af den samlede bestyrelse
Company purpose
Selskabets formål er at drive handel med medicinsk udstyr til sundhedssektoren samt al virksomhed, som er forbundet hermed, herunder men ikke begrænset til salg og distribution af medicinsk udstyr til sundhedssektoren i Danmark og at yde service, information og uddannelse til kunder
Address
Maglebjergvej 10
Email
info.dk@wellspect.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 5.045 | 11.951 | 9.419 |
| Staff expenses | -2.482 | -4.569 | -5.005 |
| EBITDA | 2.563 | 7.383 | 4.414 |
| Depreciation & amort. | -1.572 | -2.470 | -2.921 |
| EBIT | 991 | 4.913 | 1.493 |
| Net financials | -151 | -144 | -412 |
| Profit before tax | 840 | 4.768 | 1.081 |
| Tax | -0 | 931 | 416 |
| Net profit | 840 | 3.837 | 665 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 36.023 | 39.605 | 36.185 |
| Equity | 8.380 | 12.217 | 9.658 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 27.643 | 27.387 | 26.528 |
| Total debt | 27.643 | 27.387 | 26.528 |
EBITDA margin
46.9%
This company
15.8%
Market median
+197% vs market
20222024
Equity ratio
26.7%
This company
38.2%
Market median
-30% vs market
20222024
Return on equity
6.9%
This company
18.4%
Market median
-63% vs market
20222024
Net profit margin
7.1%
This company
8.1%
Market median
-12% vs market
20222024
Asset turnover
0.26×
This company
1.12×
Market median
-77% vs market
20222024
Debt / equity
2.75×
This company
0.62×
Market median
-344% vs market
20222024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2021-09-28 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
GØ Management | Management | 2021 | — | — |
JF Management | Management | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Wellspect ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Guri Ørsal Brandvold | Management | 0 companies |
| Jörg Franz Nosek | Management | 0 companies |
| Christopher Francis Schlenk | Chairman | 0 companies |
| Svenn Poulsen | Chairman | 0 companies |
| Carl Henric Olson | Board of Directors | 0 companies |
| Jimmy Emil Peder Pedersen | Board of Directors | 0 companies |